ABL Bio (298380.KQ) Q1 2026: Loss Narrows 48%, ₩186.7B in Cash
GSK and Eli Lilly upfront payments clear from receivables to cash, leaving ABL Bio debt-free on a net basis and compressing the quarterly loss to its lowest year-on-year level in two years.
Source: Q1 2026 Quarterly Report (11th Fiscal Year, January 1–March 31, 2026) — Filed May 8, 2026 with DART | Consolidated Financial Statements (ABL Bio Inc. + ABL Bio USA + NEOK Bio) | Unit: ₩ billions
The defining event of ABL Bio's first quarter of 2026 was a cash conversion, not a clinical readout. The ₩59.1 billion receivable sitting on the December 2025 balance sheet — representing the uncollected portion of Eli Lilly's USD 40 million upfront from the November 2025 Grabody-B licensing deal — arrived in cash during Q1, lifting consolidated cash and equivalents 66.8% to ₩186.7 billion and moving the net position to approximately ₩72 billion net cash (cash less total liabilities). The ₩46.0 billion in residual deferred contract liabilities remaining on the balance sheet provides a visible revenue floor for multiple future quarters without any additional licensing event. Stripping out working capital movements, underlying cash consumption ran at roughly ₩13.7 billion per quarter in Q1 — a pace at which the current cash position alone sustains over thirteen quarters of operation. For a clinical-stage biotech with no commercial products, that margin of safety is the most strategically material number on the ledger.
